Virtus Biotech ETF
16 hedge funds and large institutions have $10.2M invested in Virtus Biotech ETF in 2021 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
7% more funds holding
Funds holding: 15 → 16 (+1)
2.82% less ownership
Funds ownership: 42.47% → 39.65% (-2.8%)
16% less capital invested
Capital invested by funds: $12.2M → $10.2M (-$2M)
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$237K |
| 2 |
TC
Telemus Capital
Southfield,
Michigan
|
+$198K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$4.43K |
| 4 |
IA
IFP Advisors
Tampa,
Florida
|
+$3.75K |
| 5 |
NFG
Next Financial Group
Houston,
Texas
|
+$3.33K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.88M |
| 2 |
SMG
Smart Money Group
Eastland,
Texas
|
-$206K |
| 3 |
RWB
RMR Wealth Builders
Montclair,
New Jersey
|
-$76K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$56.6K |
| 5 |
FAIM
Financial Advocates Investment Management
Olympia,
Washington
|
-$32.7K |
BBP Hedge Fund Activity: Q2 2021 in Review
16 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech ETF (BBP) for Q2 2021, worth a combined $10.2M — down 16% from $12.2M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BBP positions and 2 closed out — a net gain of 1 holder — while 3 added to existing stakes and 6 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $237K. The largest seller was Royal Bank of Canada, cutting an estimated $1.88M.
- 16 institutional investors held Virtus Biotech ETF (BBP) as of Q2 2021, up from 15 in Q1 2021.
- Funds reported $10.2M of Virtus Biotech ETF stock for Q2 2021, down 16% quarter-over-quarter.
- 3 funds opened new Virtus Biotech ETF positions in Q2 2021 and 2 closed out, a net change of +1 holder.
- The largest Virtus Biotech ETF buyer in Q2 2021 was Susquehanna International Group, an estimated $237K added.
- The largest Virtus Biotech ETF seller in Q2 2021 was Royal Bank of Canada, an estimated $1.88M sold.
Based on aggregated 13F filings for Q2 2021.